Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV)

Pharmacoeconomics. 2003;21(14):1053-68. doi: 10.2165/00019053-200321140-00005.


Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences.

Design: A decision-analysis model. The probability of progression of the infection and of its associated care, the principal direct costs linked to them, and the effectiveness of OM-85 BV were established or calculated by reviewing the available literature (published between 1984 and 2000). Four experts validated the parameters and the model.

Results: For the French Social Security System, the mean direct cost for an acute rhinopharyngitis (ARP) infection was 49.39 Euro(2000 values). By using OM-85 BV prevention, 1.52 infections were prevented in 6 months saving 67.83 Euro on the costs of care for the recurrently infected child. Sensitivity analyses confirmed the robustness of the model and indicated a saving of between 6.28 Euro and 303.64 Euro in direct costs for each individual treated preventively. Threshold analyses showed that OM-85 BV prophylaxis is economically profitable if more than 0.15 infections are prevented and if direct costs of care of an ARP are greater than 4.78 Euro.

Conclusion: Non-specific immunotherapy should be considered for the child at risk of RARP and administered in addition to other recommended measures. The economic savings for the community of using a medication for which the clinical effectiveness has been demonstrated should also be taken into account in assessing its usefulness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / economics*
  • Adjuvants, Immunologic / therapeutic use
  • Adolescent
  • Anti-Infective Agents / economics
  • Anti-Infective Agents / therapeutic use
  • Bacteria
  • Cell Extracts / economics*
  • Cell Extracts / therapeutic use
  • Child
  • Child, Preschool
  • Common Cold / drug therapy
  • Common Cold / economics*
  • Common Cold / prevention & control*
  • Databases, Factual
  • Decision Support Techniques
  • France
  • Health Care Costs
  • Hospitalization / economics
  • Humans
  • Models, Economic
  • Recurrence
  • Risk Factors


  • Adjuvants, Immunologic
  • Anti-Infective Agents
  • Broncho-Vaxom
  • Cell Extracts